Trial Profile
Efficacy of Oral directly acting antivirals HIV/HCV-coinfected patients with genotype 3 and compensated liver disease: A real world Madrid coinfection registry (MADRID-CoRe) study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Mar 2017
Price :
$35
*
At a glance
- Drugs Daclatasvir/sofosbuvir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 23 Mar 2017 New trial record
- 16 Feb 2017 Results presented at the 24th Conference on Retroviruses and Opportunistic Infections